Oculis Holding Stock Price, News & Analysis

Oculis (Nasdaq: OCS) announced the U.S. FDA granted Breakthrough Therapy Designation to Privosegtor for treatment of optic neuritis on January 6, 2026. The designation is supported by Phase 2 ACUITY data showing an average +18‑letter gain in Low Contrast Visual Acuity (LCVA) at month 3 versus IV steroid alone, plus anatomical preservation and reduced neurofilament release. Oculis launched the registrational PIONEER program after a 2025 FDA meeting; PIONEER includes three pivotal trials and PIONEER‑1 in optic neuritis was initiated in Q4 2025 with global site activation and enrollment expected to begin shortly. The company cites a U.S. market opportunity of $7 billion for key optic neuropathies.

Oculis (OCS) announced a notification relating to the vesting and settlement of restricted stock units (RSUs) previously granted to a director. The notice names Riad Sherif and is dated January 5, 2026; an attachment titled "Notification of managers' transaction - Riad Sherif - January 2026 RSU vest" is referenced.

The announcement reports the administrative event only and does not disclose amounts, prices, or additional financial details.

Oculis (OCS) published notifications dated Dec 9, 2025 reporting the vesting and settlement of restricted stock units (RSUs) previously granted to company directors. The notifications name four directors: Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner, and indicate these RSUs vested/settled in December 2025.

These are routine managers' transaction disclosures concerning executive/director compensation events; no financial amounts or additional terms were included in the text provided.

Oculis (Nasdaq: OCS) will highlight its late-stage ophthalmology pipeline at Eyecelerator and the AAO Annual Meeting in Orlando on October 16-20, 2025.

Key updates include the acceleration of Privosegtor into registrational trials after a positive FDA meeting, topline readouts from the Phase 3 DIAMOND program for OCS-01 in diabetic macular edema expected in Q2 2026, and the planned start of the genotype-based PREDICT-1 registrational trial for Licaminlimab anticipated in Q4 2025. Presenters include CEO Riad Sherif, MD and retina advisor Arshad M. Khanani, MD.

Oculis (OCS) announced a notification concerning the vesting and settlement of restricted stock units (RSUs) previously granted to a director.

The notification identifies Arshad Khanani and records an RSU vest dated 29 November 2025.

Oculis (OTC:OCS) announced a notification of a managers' transaction relating to the vesting and settlement of restricted stock units (RSUs) previously granted to a company director.

The notification names Arshad Khanani and cites an RSU vesting event dated 25 November 2025. No financial amounts or additional transactions were disclosed.

Oculis (Nasdaq: OCS) announced that a positive FDA meeting enables a registrational development program for Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION).

The company will launch the PIONEER program with three pivotal trials: PIONEER-1 (AON, expected Q4 2025), PIONEER-2 (AON, 1H 2026) and PIONEER-3 (NAION, mid-2026). Primary endpoint: low-contrast visual acuity at 3 months. Trials will mirror Phase 2 ACUITY dosing/enrollment. Oculis reported ≈$182 million cash and short-term investments as of Sept 30, 2025, with a cash runway into 2H 2027. Management will host an analyst call today at 8:30 AM ET.

Oculis (SIX:OCS) announced a notification dated November 18, 2025 reporting a purchase of ordinary shares by a member of the company's Board of Directors.

The notice references an attachment named notification-of-managers-transaction-lionel-carnot-november-2025, indicating the transaction involves director Lionel Carnot.

Oculis (Nasdaq: OCS) announced positive Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis, to be presented at ECTRIMS 2025 on September 24, 2025, 08:30 CET by Céline Louapre, M.D., Ph.D.

Topline findings reported a clinically meaningful improvement of 18 letters at 3 months, preservation of retinal ganglion cells, and a favorable safety profile. Management said the data support Privosegtor’s neuroprotective potential and plans to advance the candidate into further studies, including a program targeting MS relapses.